136 related articles for article (PubMed ID: 27499010)
21. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Egger G; Aparicio AM; Escobar SG; Jones PA
Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
[TBL] [Abstract][Full Text] [Related]
22. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
23. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
24. Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
Kumar SR; Bryan JN; Esebua M; Amos-Landgraf J; May TJ
BMC Cancer; 2017 Feb; 17(1):158. PubMed ID: 28235398
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
27. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
[TBL] [Abstract][Full Text] [Related]
28. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
[TBL] [Abstract][Full Text] [Related]
29. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.
Labrecque MP; Alumkal JJ; Coleman IM; Nelson PS; Morrissey C
Endocr Relat Cancer; 2021 Jul; 28(8):T51-T66. PubMed ID: 33792558
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma.
Venza M; Visalli M; Biondo C; Lentini M; Catalano T; Teti D; Venza I
Biochim Biophys Acta; 2015 Mar; 1849(3):247-56. PubMed ID: 25497382
[TBL] [Abstract][Full Text] [Related]
31. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.
Jarrard DF; Kinoshita H; Shi Y; Sandefur C; Hoff D; Meisner LF; Chang C; Herman JG; Isaacs WB; Nassif N
Cancer Res; 1998 Dec; 58(23):5310-4. PubMed ID: 9850055
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116.
Fang JY; Chen YX; Lu J; Lu R; Yang L; Zhu HY; Gu WQ; Lu LG
Cell Res; 2004 Jun; 14(3):217-26. PubMed ID: 15225415
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor expression in androgen-independent prostate cancer cell lines.
Chlenski A; Nakashiro K; Ketels KV; Korovaitseva GI; Oyasu R
Prostate; 2001 Apr; 47(1):66-75. PubMed ID: 11304731
[TBL] [Abstract][Full Text] [Related]
34. CACUL1 functions as a negative regulator of androgen receptor in prostate cancer cells.
Choi H; Lee SH; Um SJ; Kim EJ
Cancer Lett; 2016 Jul; 376(2):360-6. PubMed ID: 27085459
[TBL] [Abstract][Full Text] [Related]
35. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
Kim J; Park H; Im JY; Choi WS; Kim HS
Anticancer Res; 2007; 27(5A):3285-92. PubMed ID: 17970072
[TBL] [Abstract][Full Text] [Related]
36. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.
Wang LG; Beklemisheva A; Liu XM; Ferrari AC; Feng J; Chiao JW
Mol Carcinog; 2007 Jan; 46(1):24-31. PubMed ID: 16921492
[TBL] [Abstract][Full Text] [Related]
37. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.
Schayek H; Bentov I; Jacob-Hirsch J; Yeung C; Khanna C; Helman LJ; Plymate SR; Werner H
Horm Metab Res; 2012 Jun; 44(7):511-9. PubMed ID: 22495974
[TBL] [Abstract][Full Text] [Related]
38. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells.
Singal R; van Wert J; Bashambu M
Cancer Res; 2001 Jun; 61(12):4820-6. PubMed ID: 11406558
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells.
Lee EJ; Lee BB; Kim SJ; Park YD; Park J; Kim DH
Int J Oncol; 2008 Oct; 33(4):767-76. PubMed ID: 18813790
[TBL] [Abstract][Full Text] [Related]
40. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
